Juva Life Inc JUVAF

Healthcare

Juva Life Inc. is a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution. It is vertically integrated and consists of five divisions: Juva Cultivation, Juva Research, Juva Manufacturing, Juva Distribution, and Juva Retail. Juva Cultivation focuses on cultivating and distributing cannabis to medical and recreational cannabis users. Juva Retail is a network of retail cannabis facilities that serves the San Francisco Bay Area and other areas. Juva Research researches and develops cannabis products to deliver the right medicine to the right patient at the right time. Juva Manufacturing create both Juva branded as well as white-label products for other recreational and medical related cannabis companies. Juva Distribution distributes Juva cultivated bulk cannabis, Juva branded products and may distribute products from other licensed cannabis companies.

GREY:JUVAF - Post by User

Juva Life Inc > Arbitrage

<< Previous

Bullboard Posts

Next >>

Comment by Richmondon Mar 08, 2022 5:16am

114 Views

Post# 34493864

RE:RE:Arbitrage

Chopolek will get shiitt for funds now. Canadians, don't get fooled but REPORT this crook to SEC and fet him arrested...

SpaceLabs wrote: Have you tried any of that to see if it works or not M1234?

Seems like a HOAX by Doug Chlopeek. to raise more funds from Canadians again?

Matteo1234 wrote: Big boys stealing your shares in a illiquid stock. Stayhard...The news follows the Company’s identification of non-cannabinoid compound JUVA-019, on which the Company has filed a patent application and has conducted preclinical research showing that the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. Through its research division, Juva scientists have continuously been evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit, leading to the identification of the two proprietary compounds: JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further pre-clinical investigation. Current efforts are focused on advancing both compounds through phenotypic models of chronic diseases of aging.